Babar Bashir, MD, MS
Associate Professor of Medical Oncology
Associate Professor of Pharmacology, Physiology, & Cancer Biology
![Bashir, Babar](/content/academic/academics/colleges-schools-institutes/skmc/departments/medical-oncology/faculty/bashir/_jcr_content/profile/image.img.jpg)
Contact
1025 Walnut Street
Suite 700
Phialdelphia, PA 19107
215-503-5097
215-503-3408 fax
Babar Bashir, MD, MS
Associate Professor of Medical Oncology
Associate Professor of Pharmacology, Physiology, & Cancer Biology
Research & Clinical Interest
I am currently an Assistant Professor with a primary appointment in the Department of Medical Oncology, Division of Solid Tumors, and a secondary appointment in the Department of Pharmacology, Physiology, & Cancer Biology at Thomas Jefferson University. At my prior laboratory research I defined the pathophysiology of silencing of tumor suppressors in colorectal neoplasms originating from the serrated and microsatellite instability pathways. Currently, I continue to engage in translational research with bench to bedside translation of novel therapies and early drug development. I am the PI of a Phase 2A cancer vaccine (Ad5.F35-hGCC-PADRE) study to prevent tumor recurrence in gastrointestinal adenocarcinomas. This novel GUCY2C-targerted vaccine is being developed for the secondary prevention of metastases in patients with cancers of the colon, rectum, esophagus, stomach, and pancreas with minimal residual disease. I am also spearheading the clinical development of a novel first-in-human GUCY2C-directed CAR-T therapy in advanced colorectal cancers. I also serve as the scientific co-director of Early Drug Development Office at Sidney Kimmel Comprehensive Cancer Center and run various industry-sponsored clinical trials. At the onset of COVID-19 pandemic, I participated in various national efforts to study the interaction between COVID-19 and cancer (the COVID-19 cancer consortium (CCC-19), NCI COVID-19 in Cancer Patients Study (NCCAPS)).
Education
Medical School
MD, Quaid-e-Azam Medical College, Bahawalpur, PAKISTAN, 2006
Residency
Chief Medical Resident, Abington Hospital – Jefferson Health, Abington, PA, completed 2015
Internal Medicine, Abington Hospital – Jefferson Health, Abington, PA, 2014
Fellowship
NIH T32 Research Fellow in Clinical Pharmacology, Thomas Jefferson University, Philadelphia, PA, 2018
Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, 2019
Additional Education
MS – Thomas Jefferson University, Philadelphia, PA, 2018
Publications
- Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma
- Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
- Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis
- Emerging role of circulating tumor DNA for early detection of recurrence in biliary tract cancers
- A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
Certifications
2022 – Defense Congressionally Directed Medical Research Program (No. W81XWH-22-1-0208)
2019 – ASCO/ AACR Workshop on Methods in Clinical Cancer Research
2018 – Dean’s Award for Outstanding Thesis, Thomas Jefferson University
2018 – Travel Award, 17th Annual Southeastern Fellows Research Skills Workshop by Duke University, Outerbansk, NC
2017 – Duke’s Anticancer Agent Development (DAAD) Travel Scholarship
2013 – Frobese Scholar Award, Abington Hospital – Jefferson Health, Abington, PA
Awards
Internal Medicine – 2014
Medical Oncology - 2020